Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 7, 2004, Pages 786-792

  Combes, Alain ^a   Luyt, Charles Edouard ^b   Fagon, Jean Yves ^b   Wollf, Michel ^b   Trouillet, Jean Louis ^b   Gibert, Claude ^b   Chastre, Jean ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

Antibiotic resistant bacteria; Multivariate models; Outcome assessment; Respiration, artificial

Indexed keywords

OXACILLIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; OUTCOMES RESEARCH; PENICILLIN RESISTANCE; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SUPERINFECTION; VENTILATOR;

AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BRONCHOSCOPY; CROSS INFECTION; FEMALE; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; MORBIDITY; MULTIPLE ORGAN FAILURE; PARIS; PNEUMONIA, STAPHYLOCOCCAL; RECURRENCE; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCUS AUREUS; SUPERINFECTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 4644332921     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200403-346OC     Document Type: Article

References (47)

1. Jevons MP. Celbin-resistant staphylococci. BMJ 1961;1:124-125.
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-498.
3. Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus auretis. Clin Infect Dis 1995;21:1417-1423.
4. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002;162:2229-2235.
5. Talon D, Woronoff-Lemsi MC, Limat S, Bertrand X, Chatillon M, Gil H, Dupond JL. The impact of resistance to methicillin in Staphylococcus aureus bacteremia on mortality. Eur J Intern Med 2002;13:31-36.
6. Conterno LO. Wey SB, Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998;19: 32-37.
7. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, Briggs JP, Sexton DJ, Kaye KS. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598.
8. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-59.
9. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998;158:182-189.
10. Tumbarello M, De Gaetano Donati K, Tacconelli E, Citton R, Spanu T, Leone F, Fadda G, Cauda R. Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. J Antimicrob Chemother 2002;50:375-382.
11. Soriano A, Martinez JA, Mensa J, Marco F, Almela M, Moreno-Martinez A, Sanchez F, Munoz I, Jimenez de Anta MT, Soriano E. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000;30:368-373.
12. Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch Intern Med 2000;160:1001-1004.
13. Mylotte JM, Tayara A. Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin Infect Dis 2000;31:1170-1174.
14. French GL, Cheng AF, Ling JM, Mo P, Donnan S. Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence. J Hosp Infect 1990;15:117-125.
15. Selvey LA, Whitby M, Johnson B. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia: is it any worse than nosocomial methicillin-sensitive Staphylococcus aureus bacteremia? Infect Control Hosp Epidemiol 2000;21:645-648.
16. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-1177.
17. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474.
18. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
19. Rello J, Torres A, Ricart M, Valles J, Gonzalez J, Artigas A, Rodriguez-Roisin R. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994;150:1545-1549.
20. Lentino JR, Hennein H, Krause S, Pappas S, Fuller G, Schaaff D, DiCostanzo MB. A comparison of pneumonia caused by gentamicin, methicillin-resistant and gentamicin, methicillin-sensitive Staphylococcus aureus: epidemiologic and clinical studies. Infect Control 1985;6:267-272.
21. Combes A, Luyt C, Fagon J, Wolff M, Trouillet JL, Gibert C, Chastre J. Impact of Methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia [abstract]. Am J Respir Crit Care Med 2004;169:A865.
22. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-2598.
23. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stephan F, Similowski T, Mercat A, Diehl JL, Sollet JP, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000;132:621-630.
24. Comité de l'Antibiogramme de la Societe Française de Microbiologie report 2003. Int J Antimicrob Agents 2003;21:364-391.
25. McCabe WR, Jackson GG. Gram-negative bacteremia. Arch Intern Med 1962;110:847-864.
26. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-2963.
27. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-710.
28. Fagon JY, Chastre J, Novara A, Medioni P, Gibert C. Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med 1993;19:137-144.
29. Weinberg PF, Matthay MA, Webster RO, Roskos KV, Goldstein IM, Murray JF. Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am Rev Respir Dis 1984;130:791-796.
30. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-824.
31. Katz MA. Mutivariate analysis. New York: Cambridge University Press; 1999.
32. Mekontso-Dessap A, Kirsch M, Brun-Buisson C, Loisance D. Poststernotomy mediastinitis due to Staphylococcus aureus: comparison of methicillin-resistant and methicillin-susceptible cases. Clin Infect Dis 2001; 32:877-883.
33. Combes A, Trouillet JL, Joly-Guillou ML, Chastre J, Gibert C. The impact of methicillin resistance on the outcome of poststernotomy mediastinitis due to Staphylococcus aureus. Clin Infect Dis 2004;38: 822-829.
34. Lucet JC, Chevret S, Durand-Zaleski I, Chastang C, Regnier B. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med 2003;163:181-188.
35. Schmitz FJ, MacKenzie CR, Geisel R, Wagner S, Idel H, Verhoef J, Hadding U, Heinz HP. Enterotoxin and toxic shock syndrome toxin-1 production of methicillin resistant and methicillin sensitive Staphylococcus aureus strains. Eur J Epidemiol 1997;13:699-708.
36. Hewitt JH, Sanderson PJ. The effect of methicillin on skin lesions in guinea-pigs caused by methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Med Microbiol 1974;7:223-235.
37. Cutler RR. Relationship between antibiotic resistance, the production of virulence factors and virulence for experimental animals in Staphylococcus aureus. J Med Microbiol 1979;12:55-62.
38. Ward TT. Comparison of in vitro adherence of methicillin-sensitive and methicillin-resistant Staphylococcus aureus to human nasal epithelial cells. J Infect Dis 1992;166:400-404.
39. Vaudaux P, Waldvogel FA. Methicillin-resistant strains of Staphylococcus aureus: relation between expression of resistance and phagocytosis by polymorphonuclear leukocytes. J Infect Dis 1979;139:547-552.
40. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-680.
41. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-1231.
42. Cruciani M, Gatti G, Lazzarini L, Furlan G, Broccali G, Malena M, Franchini C, Concia E. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-869.
43. Lamer C, deBeco V, Soler P, Calvat S, Fagon JY, Dombret MC, Farinotti R, Chastre J, Gibert C. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993;37:281-286.
44. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-1480.
45. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-1797.
46. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-1490.
47. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157:531-539.